Paper Details

  1. Home
  2. Paper Details

LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF-κB and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects.

Author: BertinatRomina, CastilloMaría Paz, DupratFelix, González-ChavarríaIván, JaraNery, MondacaMarcela, PazCristian, RivasYerko, RoaFrancisco, RoblesCatalina, ToledoJorge

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

The oxidized low-density lipoprotein receptor 1 (LOX-1) is implicated in atherosclerosis and other diseases, including prostate cancer. This study investigates the role of oxLDL/LOX-1 signaling in enzalutamide-resistant prostate cancer cells. The findings suggest that oxLDL/LOX-1 promotes resistance by activating NF-κB and STAT3, increasing AR and AR-V7 expression, and reducing enzalutamide cytotoxicity.
Paper Details　
Original Abstract of the Article :
The oxidized low-density lipoprotein receptor 1 (LOX-1) is one of the most important receptors for modified LDLs, such as oxidated (oxLDL) and acetylated (acLDL) low-density lipoprotein. LOX-1 and oxLDL are fundamental in atherosclerosis, where oxLDL/LOX1 promotes ROS generation and NF-κB activation...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10049196/

データ提供：米国国立医学図書館（NLM）

LOX-1: A New Player in Prostate Cancer Resistance

Prostate cancer, a formidable foe in the desert of human health, often develops resistance to treatments. This study explores the role of LOX-1, a receptor involved in cardiovascular disease, in prostate cancer resistance to enzalutamide, a common treatment. It's like discovering a hidden path in the desert, leading to a previously unknown source of resistance.

LOX-1: A Hidden Pathway to Resistance

The study found that LOX-1 activation by oxidized LDL (oxLDL) promotes prostate cancer cell resistance to enzalutamide. This discovery sheds light on a previously unknown mechanism of resistance, highlighting the complex and often unexpected pathways involved in cancer progression. It's like uncovering a hidden spring in the desert, revealing a previously unknown source of water.

The Importance of Targeting LOX-1

This research highlights the need for new strategies to combat prostate cancer resistance. It's like finding a new weapon to fight a persistent enemy, a weapon that can overcome resistance and restore balance. The study suggests that targeting LOX-1 could potentially improve treatment outcomes and overcome resistance to enzalutamide, a crucial step in our fight against prostate cancer.

Dr.Camel's Conclusion

Prostate cancer, a formidable foe in the desert of human health, often develops resistance to treatments. This research sheds light on a previously unknown pathway to resistance, highlighting the complexity and adaptability of this disease. The discovery of LOX-1's role in resistance is a valuable step in our quest to overcome this formidable challenge, opening new avenues for developing more effective treatments and strategies.
Date :
  1. Date Completed 2023-03-30
  2. Date Revised 2023-03-31
Further Info :

Pubmed ID

36982155

DOI: Digital Object Identifier

PMC10049196

Related Literature

Article Analysis
・Effects of enzalutamide
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.